Fosun Pharma Announces Topline Results from Phase III Trial of AR1001 in Early Alzheimer's Disease; Global Exclusive Option Not Yet Exercised
2 day ago / Read about 0 minute
Author:小编   

Fosun Pharma Industrial, a controlled subsidiary of Fosun Pharma, previously entered into an exclusive option agreement with AriBio. Under this agreement, Fosun Pharma Industrial obtained the option to secure exclusive rights in additional licensed territories worldwide—including core markets such as the United States, Europe, and Japan—for the development, registration, manufacturing, and commercialization of drugs containing AR1001 as the active ingredient across the full spectrum of Alzheimer's disease diagnosis, prevention, and treatment. Topline data from the global, multicenter Phase III clinical trial of AR1001 in early Alzheimer's disease have now been announced. In the monotherapy population, the primary endpoint CDR-SB reached statistical significance, meeting the primary efficacy objective. In the overall population, between-group differences were observed between the treatment group and the placebo group but did not reach statistical significance. As of the announcement date, Fosun Pharma Industrial has not yet exercised the exclusive option and will subsequently evaluate the relevant study data to determine whether to exercise it.